Aeglea BioTherapeutics, Inc./$SYRE
1D1W1MYTD1Y5YMAX
About Aeglea BioTherapeutics, Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
- Ticker
- $SYRE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 125
- Headquarters
- Waltham, United States
- Website
- www.spyre.com
SYRE Metrics
BasicAdvanced
$9.1B
-
-$2.01
3.03
-
Price and volume
Market cap
$9.1B
Beta
3.03
52-week high
$108.14
52-week low
$14.51
Average daily volume
992K
Financial strength
Current ratio
18.53
Quick ratio
18.232
Profitability
Management effectiveness
Return on assets (TTM)
-19.81%
Return on equity (TTM)
-22.98%
Valuation
Price to book
9.56
Price to tangible book (TTM)
9.56
Price to free cash flow (TTM)
-55.74
Free cash flow yield (TTM)
-1.79%
Free cash flow per share (TTM)
-1.859
Growth
Earnings per share change (TTM)
-30.11%
3-year earnings per share growth (CAGR)
-69.64%
10-year earnings per share growth (CAGR)
-33.95%
SYRE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.